* Gensia Sicor Inc., of San Diego, has signed an agreement with Sankyo Co. Ltd., of Tokyo, to collaborate on a research program to discover and develop drugs for the treatment of non-insulin-dependent (Type II) diabetes. Under the terms of the agreement, Gensia will receive license fees, equity investment, research funding for three years and milestone payments from Sankyo, plus royalties on product sales. Sankyo will have exclusive, worldwide commercialization rights to all products discovered. Gensia will have co-promotion rights in North America to any commercialized product.

* Gliatech Inc., of Cleveland, reports its premarket approval application, accepted for filing by the FDA in February 1997, for Adcon-L will receive expedited review. The FDA has determined that use of Adcon-L may provide a specific public health benefit by acting as a barrier to epidural adhesion formulation after lumbar discectomy.

* Integra LifeSciences Corp., of Plainsboro, N.J., and its subsidiary, Telios Pharmaceuticals Inc., of San Diego, have obtained proprietary rights to certain cyclized Arginine-Glycine-Aspartic acid {RGD}-containing peptides. The Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office ruled that Michael Pierschbacher, senior vice president of research and development at Integra, and Erkki Ruoslahti, a consultant to Integra, were the "first to invent" the technology and are entitled to the patent. The five-year legal battle ends the dispute among Integra, Merck & Co. Inc., of Whitehouse Station, N.J., SmithKline Beecham, of London, and Asahi Glass, of Tokyo.

* MycoTox Inc., of Denver, Colo., has been awarded a Phase I grant from the Small Business Innovation Research Program, of the National Institutes of Health to develop a screen for fungal expression inhibitors. The grant will enable MycoTox to expand its antifungal screening service, MycoSelect.

* Paracelsian Inc., of Ithaca, N.Y., reports it does not expect to meet its previously announced target date of May 1997 with respect to the company's first product launch, due, in part, to recent resignations of company personnel, as well as the need to further evaluate the proposed product.